CL3-05985-016 |
Efficacy and safety of the fixed oral perindopril arginine 5mg/amlodipine 5mg combination compared with amlodipine…
|
AMLODIPINE, PERINDOPRIL ARGININE, S005985
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05985-006 |
Perindopril Amlodipine Regimen versus AT1-Receptor Blocker/thiazide: a comparison of Blood pressure Lowering: Efficacy and Safety.…
|
AMLODIPINE, PERINDOPRIL ARGININE, S005985
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05702-014 |
Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not…
|
GLICLAZIDE, S005702
|
Phase 3
|
Metabolism
|
|
CL3-05702-013 |
Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os)…
|
GLICLAZIDE, S005702
|
Phase 3
|
Metabolism
|
|
CL3-05682-108 |
Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets and micronized purified flavonoid…
|
MICRONISED PURIFIED FLAVONOID FRACTION, S005682
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05682-107 |
Clinical acceptability study of micronized purified flavonoid fraction 1000 mg, one tablet per day compared…
|
MICRONISED PURIFIED FLAVONOID FRACTION, S005682
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05682-105 |
Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day…
|
MICRONISED PURIFIED FLAVONOID FRACTION, S005682
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05590-022 |
Efficacy of perindopril/indapamide combination on coronary Pet Scan parameters. A 6 month, open non controlled…
|
INDAPAMIDE, PERINDOPRIL TERT BUTYLAMINE, S005590
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05590-013 |
A factorial randomised trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and…
|
GLICLAZIDE, INDAPAMIDE, PERINDOPRIL TERT BUTYLAMINE, S005590, S005702
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05520-006 |
Safety and efficacy of fixed dose combination of Indapamide SR 1.5 mg / Amlodipine versus…
|
AMLODIPINE, INDAPAMIDE, S005520
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05520-005 |
Safety and efficacy of fixed dose combination of Indapamide SR / Amlodipine in single-pill versus…
|
AMLODIPINE, INDAPAMIDE, S005520
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-05153-006 |
Efficacy and Safety of Fixed-Dose Combination atorvastatin/amlodipine/perindopril versus Fixed-Dose Combination of atorvastatin/ amlodipine in Patients…
|
AMLODIPINE, ATORVASTATIN, PERINDOPRIL ARGININE, S005153
|
Phase 3
|
Cardiovascular Diseases
|
|
CL3-04200-006 |
Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of…
|
PIRIBEDIL, S004200
|
Phase 3
|
Neuropsychiatric Diseases
|
|
CL3-01574-237 |
Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering…
|
TIANEPTINE, S001574
|
Phase 3
|
Neuropsychiatric Diseases
|
|
CL3-00780-150 |
International follow-up study, after the investigational drug exposure in diabetic patients previously included in the…
|
BENFLUOREX, S000780
|
Phase 3
|
Metabolism
|
|
CL3-00780-148 |
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to…
|
BENFLUOREX, S000780
|
Phase 3
|
Metabolism
|
|
CL2-RTCCAR-001 |
Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of…
|
RTCCAR
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-NEURO-005 |
Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity…
|
DONEPEZIL, MEMANTINE
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-DIABE-001 |
Assessment of blood glucose profile in type 2 diabetic patients after a one-week treatment with…
|
GLICLAZIDE
|
Phase 2
|
Metabolism
|
|
CL2-95005-003 |
Open-label multicentre confirmatory study of efficacy and safety of S 95005 (TAS-102) in patients with…
|
TIPIRACIL, TRIFLURIDINE, S095005
|
Phase 2
|
Cancers
|
|
CL2-95005-002 |
An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine…
|
TIPIRACIL, TRIFLURIDINE, S095005
|
Phase 2
|
Cancers
|
|
CL2-90652-002 |
Safety and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram…
|
PERINDOPRIL ARGININE, S090652
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-90652-001 |
Acceptability, safety, pharmacokinetics and effects on blood pressure of a daily dose of 0.025 to…
|
PERINDOPRIL ARGININE, S090652
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-90098-009 |
Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over…
|
AGOMELATINE, S090098
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-90098-005 |
Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for…
|
AGOMELATINE, S090098
|
Phase 2
|
Neuropsychiatric Diseases
|
|